Endothelial monocarboxylate transporter 1 drives atherosclerosis via a lactate/NADH/CtBP‐mediated transrepression pathway
MedComm · 2025-02 · 6 (2)
DOI: 10.1002/mco2.70089 ↗Kurz gefasst
Fachartikel in der Zeitschrift MedComm, online erschienen am 13.02.2025. Verfasst von Zou Li und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency The Second Affiliated Hospital, Guangzhou Medical University Guangzhou China. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The accumulation of lactate in tissue microenvironments is associated with atherosclerosis, but its precise role in atherogenesis remains largely unknown. This study demonstrated that lactate accumulation in aortic tissues and blood is correlated with increased monocarboxylate transporter 1 (Mct1) expression in endothelial cells (ECs) within atherosclerotic plaques. Lactate uptake via Mct1 triggers an inflammatory response in ECs. The administration of endothelial‐targeting nanoparticles containing siRNA against Mct1 reduces endothelial inflammation and atherogenesis in Apoe −/− mice. Mechanistic studies revealed that the conversion of lactate to pyruvate, along with NADH production and oligomerization of the NADH‐sensitive transcriptional corepressor C‐terminal binding protein 1 (CtBP1), is necessary for the proinflammatory effects of lactate. Monomeric CtBP1 interacts with the transcriptional repressor forkhead box P1 (FOXP1) to suppress endothelial adhesion molecule expression. However, NADH‐induced oligomerization of CtBP1 prevents its binding to FOXP1, significantly reducing FOXP1‐mediated transrepression of endothelial adhesion molecules. Moreover, silencing Foxp1 in ECs negates the atheroprotective effect of endothelial Mct1 knockdown in Apoe −/− mice. These findings suggest that lactate/MCT1‐induced epigenetic reprogramming represents a potential therapeutic target in atherosclerosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Emergency The Second Affiliated Hospital, Guangzhou Medical University Guangzhou China.
- Department of Physiology, School of Basic Medical Sciences Guangzhou Medical University Guangzhou China.
- Department of Nephrology, the Fourth Affiliated Hospital Guangzhou Medical University Guangzhou China.
- Department of Cerebrovascular Disease The Affiliated Qingyuan Hospital (Qingyuan People's Hospital) Guangzhou Medical University Qingyuan China.
- Department of Rehabilitation Center The First Affiliated Hospital of Guangzhou University of Chinese Medicine Guangzhou China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, Z., Guo, S., Cao, K., Duan, Y., Zhao, Y., Zhang, Y., Yu, S., Bai, Z., Yu, R., Chen, Y., Li, Z., Huang, S., Song, M., Wang, C., Hou, W., He, J., Yang, B., & Xu, Y. (2025). Endothelial monocarboxylate transporter 1 drives atherosclerosis via a lactate/NADH/CtBP‐mediated transrepression pathway. MedComm, 6(2). https://doi.org/10.1002/mco2.70089
Vancouver
Li Z, Guo S, Cao K, Duan Y, Zhao Y, Zhang Y, et al. Endothelial monocarboxylate transporter 1 drives atherosclerosis via a lactate/NADH/CtBP‐mediated transrepression pathway. MedComm. 2025;6(2). doi:10.1002/mco2.70089
BibTeX
@article{Li2025,
author = {Li, Zou and Guo, Shuai and Cao, Kaixiang and Duan, Yuxi and Zhao, Yuan and Zhang, Yuting and Yu, Shihui and Bai, Zaixia and Yu, Runfa and Chen, Yixin and Li, Ziling and Huang, Shuqi and Song, Mingchuan and Wang, Cailing and Hou, Wenzhong and He, Jun and Yang, Bin and Xu, Yiming},
title = {Endothelial monocarboxylate transporter 1 drives atherosclerosis via a lactate/NADH/CtBP‐mediated transrepression pathway},
journal = {MedComm},
year = {2025},
volume = {6},
number = {2},
doi = {10.1002/mco2.70089}
}
EUVIMED